The strong efficacy and safety data could drive near-term upside. Monitor for updates on the IMPACT trial and potential regulatory filings. Insider trading patterns and analyst upgrades may provide further signals.
DRTS drugs
DRTS drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $7.53entry
- T+1 · 7mo ago −1.86%α −2.65% · $7.39
- T+5 · 6mo ago +37.32%α +34.38% · $10.34
- T+20 · 6mo ago +28.35%α +22.71% · $9.67
- T+60 · 4mo ago +48.47%α +46.62% · $11.18
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alpha Tau announced 100% local disease control in evaluable patients from pooled first-in-human trials of Alpha DaRT for pancreatic cancer, presented at DDW 2026. The favorable safety and efficacy data in heavily pre-treated patients represent a significant milestone for the company's lead product candidate.
Key Facts
- 100% local disease control in 19 evaluable patients (79% stable disease, 21% partial response)
- Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
- First presentation of Alpha DaRT at a major gastroenterology conference (DDW 2026)
- Treatment delivered via EUS, designed for integration into standard GI workflow
- Ongoing U.S. multicenter pancreatic cancer IMPACT trial
Financial Impact
Positive sentiment boost; potential future revenue if approved, but no current financial impact
Risk Factors
- Data is from early-stage trials; larger studies may not replicate results
- Alpha DaRT is not yet approved for commercial use in the U.S.
- Biotech volatility; stock may have priced in expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286810 |
Track record
25 reports on DRTS
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +68.80% at T+60 after the Apr 23, 2026 report. 11 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry $14.50 Now $11.97 −17.45% settles Feb 12
- Nov 16, 2026today 6-K Bullish 6/10 Entry $15.46 Now $11.97 −22.56% settles Feb 12
- Nov 15, 20261d ago Press Release Bullish 7/10 Entry $13.35 Now $11.97 −10.34% settles Feb 12
- Nov 12, 20264d ago 6-K Neutral 3/10 Entry $13.36 Now $11.97 −10.40% settles Feb 10
- Oct 29, 202618d ago 6-K Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $13.23 Now $11.97 −9.52% settles Jan 27
- Oct 22, 202625d ago 6-K Neutral 4/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $12.90 Now $11.97 −7.21% settles Jan 20
- Oct 19, 202628d ago 6-K Bullish 6/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $12.62 Now $11.97 −5.15% settles Jan 14
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers